EU Allows Firms More Time To Make Nitrosamine-Related Manufacturing Changes
Deadline Extended To Enable Companies To Perform A Thorough Investigation
Executive Summary
The European medicines regulatory network is giving sponsors of marketed medicines that contain chemically synthesised active substances an extra 12 months to apply for manufacturing changes to address nitrosamine-related risks.
You may also be interested in...
EDQM Updates Approach To CEPs In Light Of Nitrosamine Regulatory Changes
The European Directorate for the Quality of Medicines & HealthCare has issued updates on “certificates of suitability” for manufacturers in light of new regulatory developments on addressing nitrosamine impurities in drugs.
EDQM Updates Approach To CEPs In Light Of Nitrosamine Regulatory Changes
The European Directorate for the Quality of Medicines & HealthCare has issued updates on “certificates of suitability” for manufacturers in light of new regulatory developments on addressing nitrosamine impurities in drugs.
Biologicals Join List Of EU Medicines Requiring Nitrosamine Evaluation
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.